revenue forecast from existing product pipeline (sourced from Company presentation)

Shares of Valeo Pharma Inc. (CSE: VPH) (Frankfurt: VP2) are poised for substantial upside revaluation to reflect the major company –maker potential in HesperCo™

Valeo Pharma Inc. (CSE:VPH)

NEW YORK, NY, USA, September 2, 2020 /EINPresswire.com/ -- Conceivably, in the near-term en masse, we may see a scenario develop whereby front-line workers and people concerned about the virus will want to take HesperCo™ proactively and certainly if infected to alter the viral kinetics; inhibit replication, and modulate the inflammatory response by down regulating the cytokine storm. Hesperidin (the compound making up HesperCo™) is set to undergo Covid19 clinical trials to further evidence its support of the immune system leading to speculation HesperCo™ will become a go-to tool in dealing with early-stage infection; scientific academic research supports that in the lag-time before antibodies kick-in hesperidin meaningfully keeps at bay the number of viruses the body has to neutralize.

Valeo Pharma Inc. (CSE: VPH) (Frankfurt: VP2) is the subject of a Market Bulletin Special Situation Advisory, the full copy of which may be viewed at https://marketequitiesresearch.com/marketbulletin-valeo-pharma-sept-2-2020.htm online.

Valeo Pharma is a fully integrated specialty pharmaceutical company. Valeo has announced it has entered into a collaborative effort with Ingenew Pharma Inc. to commercialize a product called HesperCo™, which is derived from the hesperidin molecule. Hesperidin is not being advanced by any big pharma as it is a public domain compound, and thus can’t be turned around and sold for $100 a pill. Valeo Pharma is not saying much about HesperCo™ at this point in time apart from it ‘supporting the immune system’, which is a catch-all phrase that basically encompasses a number of possibilities without making claims, but one look at the HesperCo™ manufacturer Ingenew’s corporate website https://ingenewpharma.com and it is clear Hesperidin has copious amounts of academic research from multiple sources supporting the role it plays in various phases of Covid19 viral infection.

See Valeo’s partner PDF on SARS-COV-2 (a.k.a. Covid-19) and how it infects the host:
https://ingenewpharma.com/wp-content/uploads/2020/07/PART-A-JUly-18-2020.pdf

See Valeo’s partner PDF on hesperidin and scientific literature search looking back at SARS-COV (previous strains):
https://ingenewpharma.com/wp-content/uploads/2020/07/PART-B-JUly-18-2020.pdf

Hesperidin is a bioflavonoid molecule, a type of plant pigment with a myriad of effects from antioxidant to anti-inflammatory, sourced primarily in select unripe citrus fruit.

The name ‘HesperCo’ (TM) comes from the upcoming clinical trial testing hesperidin on Covid19 (coronavirus) patients that Ingenew will apparently be involved with (details still to be announced, but they make reference to it at https://ingenewpharma.com/about). As a NHP, hesperidin, will bypass the need for regulatory approval (like a drug would require or a substance making health claims), however scientific evidence clearly shows hesperidin acts like a powerful drug.

Below is our synopsis of key academic research that is already understood about hesperidin;
We urge the reader to view the above PDF’s from Valeo’s partner and the supporting index of 123 research papers. The following is what we believe to be the understanding of the objectives of the HesperCo™ trial; in summary (not making health claims here, just stating the objectives of a trial based on known scientific research), hesperidin can prominently assist in the viral and patient inflammatory response phases, and potentially hesperidin covers all 4 phases of the covid19 progression.

All phases of viral infection appear to be affected in some way by hesperidin and that the earlier the patient is on hesperidin the better. When you are asymptomatic and start having fever and cough, you are in the viral response phase. Fever and cough marks the inflammatory response phase. The presence of hesperidin interferes with what would otherwise be an exponential cascade of viral S-Spike binding and HR1-HR2 replication. Since the body has no vaccine present (no memory/blueprint about how to respond) the initial lag time is when the presence of hesperidin can drastically reduce the viral load and can prevent matters from getting critical.

1) Hesperidin prevents the penetration (binding) of the novel coronavirus S-Spike protein into the cell’s Ace2 protein receptor: The spike region binding domain of the virus is the part that connects to the Ace2 receptor of a cell. Hesperidin has scientific support that indicates it causes interference in the shallow pockets that the spike attempts to bind with.

2) Hesperidin inhibits the replication of the virus: Hesperidin has scientific support in literature that it neutralizes or inhibits the 3CL protease, also referred to as the Mpro. There are now at least 5 groups that have shown, plus in vitro evidence, that hesperidin can essentially inhibit the 3CL probe replication protein. Once infected, the 3CL is a key protein in the virus replication, and with hesperidin present to cause a neutralizing effect on the 3CL, replication is dramatically hindered.

3) Hesperidin modulates inflammation and biomarkers: The coronavirus affects multiple organs; infecting and dysregulating the CNS System, the respiratory system, cardiovascular system, etc. Hesperidin has scientific evidence that it can play an active role in modulating inflammation and biomarkers, which by default reduces the cytokine storm.

4) Hesperidin attenuates ventilator induced acute lung injury: Although hesperidin is ideally taken orally for EARLY–stage mitigation, it has significant scientific support in its ability to attenuate ventilator induced acute lung injury. If a person is at such an acute stage they would not be taking HesperCo™ as currently the product is over-the-counter oral, but it is comforting to know the science is there on that front too. There is already talk of an alternate form of delivery for the product under development.

What does all this mean for investors in Valeo Pharma Inc.? HesperCo™ is trademarked by Ingenew and licensed to Valeo. Valeo has world-wide rights, it has filed in Canada, it already has product and packaging ready for delivery, is expected to launch within weeks (once issued its NHP, imminent), and is expected to follow into the USA shortly thereafter. Ingenew’s clinical trial is “the HesperCo™ Clinical Trial”. From what is known to date academically Ingenew and Valeo appear to have the potential for a home-run, this has the earmarks of a run-away freight train home-run company-maker. Keep your eye on shares of CSE:VPH.

See full copy at https://marketequitiesresearch.com/marketbulletin-valeo-pharma-sept-2-2020.htm online.

The above content is not a solicitation to buy or sell any securities mentioned, content is for information purposes only and not advise.

Fredrick William
Market Equities Research Group
+1 866-620-9945
email us here